New Jersey A3242 mandates health insurers to cover continuous glucose monitoring systems for glycogen storage disease treatment.

New Jersey A3242 requires health insurers to provide coverage for continuous glucose monitoring systems, prescribed for glycogen storage disease treatment. This applies to various health benefit plans, including hospital service corporations, health service corporations, medical service corporations, health maintenance organizations, individual and group health insurers, and small employer health benefits plans. The benefits must be provided to the same extent as for any other medical condition under the plan. The act takes effect on the first day of the seventh month following enactment.

New Jersey A3242 mandates health insurers to cover continuous glucose monitoring systems for glycogen storage disease treatment.

New Jersey A3242 requires health insurers to provide coverage for continuous glucose monitoring systems, prescribed for glycogen storage disease treatment. This applies to various health benefit plans, including hospital service corporations, health service corporations, medical service corporations, health maintenance organizations, individual and group health insurers, and small employer health benefits plans. The benefits must be provided to the same extent as for any other medical condition under the plan. The act takes effect on the first day of the seventh month following enactment.